	Atogepant		Placebo		Risk Difference		Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Ailani 2021	385	659	62	214	35.5%	0.29 [0.22, 0.37]	-
Goadsby 2020	342	617	72	178	33.7%	0.15 [0.07, 0.23]	-
Tassorelli 2024	78	154	28	155	30.8%	0.33 [0.23, 0.43]	-
Total (95% CI)		1430		547	100.0%	0.26 [0.15, 0.36]	•
Total events	805		162				
Heterogeneity: $Tau^2 = 0.01$; $Chi^2 = 9.48$, $df = 2$ (P = 0.009); $I^2 = 79\%$						% ⊢ -1	-0.5 0 0.5 1
Test for overall effect: $Z = 4.76$ (P < 0.00001)						-1	-0.5 0 0.5 1 Favours [Placebo] Favours [Atogepant]

Supplementary Figure 3. Analysis of ≥50% reduction in monthly migraine days for combined atogepant dosages vs. placebo.